Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C. Gerstein, Anselmo P. Bordonava, Helen M. Colhoun et al.|The Lancet|2019Cited by 3.1k
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHertzel C. Gerstein, Anselmo P. Bordonava, Helen M. Colhoun et al.|The Lancet|2019Cited by 640
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 DiabetesRajiv Agarwal, Anantharaman Vathsala, Katja Rohwedder et al.|Annals of Internal Medicine|2023Cited by 94
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD StudyJanusz Gumprecht, Ellen Burgess, Rajiv Agarwal et al.|Diabetes Care|2022Cited by 36